Biognosys Expands Co-Marketing Agreement with Global Life Science Leader to Advance Proteomics
14.12.2021 18:00:00 EET | Business Wire | Press release
Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.
The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.
Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.
Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”
Through the companies’ extended co-marketing agreement, laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”
Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.
Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.
The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.
Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics”, during the Thermo Fisher Scientific dinner workshop at ASMS 2021.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/
Contact information
Media Contact
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom